Hervé Ghesquières - Concepedia

Author

Hervé Ghesquières

Also Known As

Cozen, W., E Frobert, Ghesquieres, Herve, Ghesquieres, Hervé, Ghesquières, Hervé, Gilles Salles, H Ghesquieres, H Ghesquières, H Ghésquières, H. Ghesquieres

527

Publications

11K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Hôpital Lyon Sud Hospices Civils de Lyon Université Claude Bernard Lyon 1 Inserm

About

Hervé Ghesquières is an author at Centre Léon Bérard specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	53	3.9K
2	Health Sciences	14	16	660
3	Public Health	3	3	264
4	Engineering	1	1	20
5	Cell Biology	1	1	21

Hervé Ghesquières

131

Publications

9.3K

Citations

H-Index

Page 1

	Year	Citations
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières, Journal of Clinical Oncology	2022	484
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, Journal of Clinical Oncology	2014	399
International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Blood	2020	357
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial Christian Récher, Bertrand Coiffier, Corinne Haïoun, The Lancet Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyPathology	2011	356
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network Carole Soussain, Sylvain Choquet, Marie Blonski, European Journal of Cancer Neuro-oncologyPrimary Vitreoretinal LymphomaLymphoid NeoplasiaOphthalmologyMedicine	2019	305
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial Richard Delarue, Hervé Tilly, Nicolas Mounier, The Lancet Oncology Hematological MalignancyDose-dense Rituximab-chopStandard Rituximab-chopLymphoid NeoplasiaElderly Patients	2013	298
Recurrent Mutations of <i>MYD88</i> and <i>TBL1XR1</i> in Primary Central Nervous System Lymphomas Alberto González-Aguilar, Ahmed Idbaïh, Blandine Boisselier, Clinical Cancer Research	2012	236
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts Clémentine Sarkozy, Matthew J. Maurer, Brian K. Link, Journal of Clinical Oncology	2018	230
Management and outcome of primary CNS lymphoma in the modern era Caroline Houillier, Carole Soussain, Hervé Ghesquières, Neurology	2020	229
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma Matthew J. Maurer, Emmanuel Bachy, Hervé Ghesquières, American Journal of Hematology Lymphoid NeoplasiaCancer EpidemiologyMedicineEpidemiology Of CancerClinical Epidemiology	2016	219

Page 1